Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | GCK | P35557 | 5/20 | 0.51 |
| ▸ | RARA | P10276 | 1/20 | 0.51 |
| ▸ | RARB | P10826 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1426967 | 0.91 | LMNA (0.55) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL1042331 | 0.91 | LMNA (0.55) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL12408453 | 0.90 | LMNA (0.54) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL2662217 | 0.90 | LMNA (0.54) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL1427108 | 0.90 | LMNA (0.54) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL1042436 | 0.90 | LMNA (0.54) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL1427184 | 0.90 | GCK (0.61) | LMNAHPGDMEN1KMT2AGCK | |
| SCHEMBL27669621 | 0.88 | MEN1 (0.73) | MEN1KMT2AGCKRARARARB | |
| SCHEMBL2084645 | 0.88 | GCK (0.59) | LMNAHPGDGCKRARARARB | |
| SCHEMBL2666120 | 0.88 | MEN1 (0.73) | MEN1KMT2AGCKRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | PHARMACIA CORPORATION (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2007-04-05 | — | — | US | disclosed |
| EP-1682509-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | AstraZeneca AB (SE) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005044801-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
| WO-2005044801-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | ASTRAZENECA AB (SE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078168-A1 | PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS | GCK, GCKR, GALK1 | LMNA 3459/4885HPGD 963/4885MEN1 2732/4885 |
| US-20070167621-A1 | SUBSTITUTED PYRIMIDINONES | MAPK1, MAP3K8, MAP3K7 | LMNA 3164/4885HPGD 418/4885MEN1 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.